Healthy Clinical Trial
— LISAOfficial title:
Assessment of the Daily Average Requirement of Iodine in Lactating Women: A Dose-response Metabolic Balance Study
NCT number | NCT05382793 |
Other study ID # | BASEC2022-00130 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 16, 2022 |
Est. completion date | July 2024 |
Human milk is the only source of iodine during early infancy and adequate iodine intake during lactation is necessary to assure optimal thyroid function in breastfed infants. However, the physiological requirement of iodine in lactating women is uncertain and recommendations for the daily dietary average requirement are poorly defined. WHO recommends iodine supplementation to lactating women in populations with incomplete coverage of iodized salt and deficient iodine intake, but the scientific evidence is weak and the optimal dose is uncertain. The primary objective is to assess the daily dietary average requirement for iodine in lactating women. Secondary objectives are to: - Estimate the daily average requirement for iodine in exclusively breastfed infants; - Assess the dose-response of dietary iodine supplements on breast milk iodine concentration in lactating women with adequate and inadequate habitual iodine intakes; - Estimate the maternal iodine intake required to provide exclusively breastfed infants with an adequate iodine intake via breast milk.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | July 2024 |
Est. primary completion date | November 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Mother-infant pairs in good health, free of any acute illness or chronic thyroid disease. Mothers Inclusion criteria: 1. Consent to enroll herself and her baby; 2. Age 18 to 49 years; 3. Singleton pregnancy; 4. Exclusively breastfeeding; 5. Self-estimated BMI <30 kg/m2 before conception. Exclusion criteria: 1. TSH >6 mIU/L; 2. Anemia (Hb <11.7 g/L); 3. Pregnancy (self-reported); 4. Acute illness (e.g. gastroenteritis); 5. History of thyroid disease, diabetes, metabolic disease or inflammatory bowel disease (self-reported); 6. Currently smoking (>1 cigarette/day); 7. Drug abuse or extensive alcohol intake; 8. Exposure to iodine-containing X-ray or computed tomography contrast agents during the past 6 months; 9. Adenomatous goiter, dermatitis, anti-C1q-vasculitis. Infants Inclusion criteria: 1. Full term (38-42 weeks); 2. Birthweight =2.5 kg; 3. Exclusively breastfed; 4. Age 0-10 weeks at recruitment. Exclusion criteria: 1. Age >6 months; 2. TSH >10 mIU/L at neonatal screening at 2-5 days after birth (i.e. infants not requested to attend recall assessment); 3. Diagnosed or suspected colic. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Nutrition Research Unit, University Children's Hospital Zurich | Zürich |
Lead Sponsor | Collaborator |
---|---|
University Children's Hospital, Zurich | ETH Zurich (Switzerland) |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maternal iodine retention (µg/day) | Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day) | 24 hours | |
Secondary | Maternal iodine excretion in breast milk (µg/day) | Estimated from measured breast milk iodine concentration (µg/L) and breast milk volume (L) | 24 hours | |
Secondary | Infant iodine retention (µg/day) | Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day) | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |